Saliva Diagnostics delists from Nasdaq:
This article was originally published in Clinica
Saliva Diagnostics has left the Nasdaq SmallCap market because it says it does not meet the new listing standards required by the market. The rapid diagnostics company plans to have itself listed on the OTC Bulletin Board in the near future. The company recently completed a private placement of 6% preferred stock at $1.5 million which is convertible into ordinary shares at the end of April.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.